Clovis Oncology, Inc. Contracts & Agreements

107 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Manufacturing Services Agreement (the “Agreement”)
Services Agreements
Clovis Oncology, Inc.
Biotechnology
2017
Asset Purchase Agreement, dated as of April 5, 2023, by and between Clovis Oncology, Inc. and pharma& Schweiz GmbH
Purchase Agreements
Clovis Oncology, Inc.
2023
Secured Superpriority Debtor-In-Possession Financing Agreement, dated as of January 6, 2023, by and among the Company, as borrower, Clovis Ireland and Clovis UK, as guarantors,...
Financing Agreements
Clovis Oncology, Inc.
2023
Pledge and Security Agreement, dated as of January 6, 2023, by and among the Company certain subsidiaries of the Company, as grantors, and the Administrative Agent
Security Agreements
Clovis Oncology, Inc.
2023
DIP Term Sheet
Term Sheets
Clovis Oncology, Inc.
2022
Purchase and Assignment Agreement, dated as of December 11, 2022, by and between Clovis Oncology, Inc. and Novartis Innovative Therapies AG
Purchase Agreements
Clovis Oncology, Inc.
Biotechnology
NY
2022
Superpriority Debtor-In-Possession Facility Commitment Letter, dated as of December 11, 2022, by and among Clovis Oncology, Inc. and the Commitment Parties
Clovis Oncology, Inc.
2022
Distribution Agreement, dated August 16, 2021, by and among Clovis Oncology, Inc., J.P. Morgan Securities LLC and BofA Securities, Inc
Distribution Agreements
Clovis Oncology, Inc.
Biotechnology
NY
2021
Clovis Oncology, Inc. Amended and Restated 2020 Stock Incentive Plan
Bonus & Incentive Agreements
Clovis Oncology, Inc.
2021
Clovis Oncology, Inc. 2021 Employee Stock Purchase Plan
Stock Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2021
Indemnification Agreement, dated as of July 12, 2021, by and between Clovis Oncology, Inc. and Ronit Simantov
Indemnification Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2021
Distribution Agreement, dated May 17, 2021, by and among Clovis Oncology, Inc., J.P. Morgan Securities LLC and BofA Securities, Inc
Distribution Agreements
Clovis Oncology, Inc.
2021
Employment Agreement, dated as of May 4, 2021, by and between Clovis Oncology, Inc. and Thomas C. Harding
Employment Agreements
Clovis Oncology, Inc.
2021
Indemnification Agreement, dated as of May 3, 2021, by and between Clovis Oncology, Inc. and Thomas C. Harding
Indemnification Agreements
Clovis Oncology, Inc.
2021
License and Collaboration Agreement, dated September 20, 2019 by and between 3B Pharmaceuticals GmbH and Clovis Oncology, Inc
Collaboration Agreements
Clovis Oncology, Inc.
Biotechnology
CO
2021
Indenture, dated as of November 17, 2020, by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to the New 2024 Notes
Indenture Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2020
Form of Indenture, to be entered into by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, relating to the New 2024 Notes
Indenture Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2020
Form of Exchange and Purchase Agreement
Exchange Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2020
Clovis Oncology, Inc. 2020 Stock Incentive Plan
Bonus & Incentive Agreements
Clovis Oncology, Inc.
Biotechnology
CO
2020
Form of Clovis Oncology, Inc. 2020 Stock Incentive Plan Option Grant Notice and Agreement
Bonus & Incentive Agreements
Clovis Oncology, Inc.
2020
Form of Clovis Oncology, Inc. 2020 Stock Incentive Plan Restricted Stock Unit Grant Notice and Agreement
Bonus & Incentive Agreements
Clovis Oncology, Inc.
2020
Underwriting Agreement, dated May 18, 2020
Underwriting Agreements
Clovis Oncology, Inc.
2020
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
Clovis Oncology, Inc.
2020
Indenture, dated as of August 13, 2019, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee
Indenture Agreements
Clovis Oncology, Inc.
2019
Pledge and Security Agreement, dated as of May 1, 2019 among each of the Grantors party thereto and the Administrative Agent party thereto
Security Agreements
Clovis Oncology, Inc.
Biotechnology
2019
Financing Agreement, dated as of May 1, 2019 among Clovis Oncology, Inc. (the Company), certain subsidiaries of the Company named therein, as Guarantors, the Lenders from time to...
Financing Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2019
Amendment to Employment Agreement, by and between Clovis Oncology, Inc. and Patrick Mahaffy, dated March 14, 2019
Employment Agreements
Clovis Oncology, Inc.
2019
Amendment to Employment Agreement, by and between Clovis Oncology, Inc. and Daniel Muehl, dated March 14, 2019
Employment Agreements
Clovis Oncology, Inc.
2019
Amendment to Employment Agreement, by and between Clovis Oncology, Inc. and Gillian Ivers-Read, dated March 14, 2019
Employment Agreements
Clovis Oncology, Inc.
Biotechnology
CO
2019
Amendment to Employment Agreement, by and between Clovis Oncology, Inc. and Paul Gross, dated March 14, 2019
Employment Agreements
Clovis Oncology, Inc.
Biotechnology
CO
2019
Amended and Restated Employment Agreement, dated as of February 27, 2019, by and between Clovis Oncology, Inc. and Clovis Oncology UK Limited and Lindsey Rolfe
Employment Agreements
Clovis Oncology, Inc.
Biotechnology
CO
2019
Employment Agreement, dated as of July 6, 2017, between Clovis Oncology, Inc. and Paul Gross
Employment Agreements
Clovis Oncology, Inc.
2019
Indemnification Agreement, dated as of September 9, 2016, between Clovis Oncology, Inc. and Paul Gross
Indemnification Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2019
Indemnification Agreement, dated as of October 11, 2018, by and between Clovis Oncology, Inc. and Robert W. Azelby
Indemnification Agreements
Clovis Oncology, Inc.
2018
Indemnification Agreement, dated as of October 11, 2018, by and between Clovis Oncology, Inc. and Richard A. Fair
Indemnification Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2018
Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan, as amended
Stock Agreements
Clovis Oncology, Inc.
2018
Underwriting Agreement, dated April 16, 2018
Underwriting Agreements
Clovis Oncology, Inc.
Biotechnology
NY
2018
Underwriting Agreement, dated April 16, 2018
Underwriting Agreements
Clovis Oncology, Inc.
2018
Indenture, dated April 19, 2018
Indenture Agreements
Clovis Oncology, Inc.
2018
First Supplemental Indenture, dated April 19, 2018
Indenture Agreements
Clovis Oncology, Inc.
Biotechnology
NY
2018
EMPLOYMENT AGREEMENT
Employment Agreements
Clovis Oncology, Inc.
2017
CLOVIS ONCOLOGY, INC. 3,409,091Shares of Common Stock (par value $0.001 per share) Underwriting Agreement
Underwriting Agreements
Clovis Oncology, Inc.
2017
Strata Trial Collaboration Agreement
Collaboration Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2017
RESTRICTED STOCK UNIT GRANT NOTICE AND AGREEMENT
Stock Agreements
Clovis Oncology, Inc.
Biotechnology
2017
CLOVIS ONCOLOGY, INC. 5,000,000Shares of Common Stock (par value $0.001 per share) Underwriting Agreement
Underwriting Agreements
Clovis Oncology, Inc.
2017
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. First Amendment to License Agreement between Clovis...
Management Agreements
Clovis Oncology, Inc.
Biotechnology
2016
CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT
Indemnification Agreements
Clovis Oncology, Inc.
2016
CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT
Indemnification Agreements
Clovis Oncology, Inc.
2016
EMPLOYMENT AGREEMENT
Employment Agreements
Clovis Oncology, Inc.
Biotechnology
CO
2016
CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT
Indemnification Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2016
EMPLOYMENT AGREEMENT
Employment Agreements
Clovis Oncology, Inc.
2016
CLOVIS ONCOLOGY, INC.
Clovis Oncology, Inc.
2015
CLOVISONCOLOGY, INC. 3,525,641 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement
Underwriting Agreements
Clovis Oncology, Inc.
2015
CLOVISONCOLOGY, INC. AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of September 9, 2014 2.50% Convertible Senior Notes due 2021 TABLE OF...
Indenture Agreements
Clovis Oncology, Inc.
2014
CLOVISONCOLOGY, INC. 2,000,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement
Underwriting Agreements
Clovis Oncology, Inc.
2013
STOCK PURCHASE AGREEMENT by and among CLOVISONCOLOGY, INC., EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A., THE SELLERS LISTED ON EXHIBIT A HERETO, and SOFINNOVA CAPITALV FCPR, as the...
Stock Agreements
Clovis Oncology, Inc.
2013
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreements
Clovis Oncology, Inc.
Biotechnology
NY
2013
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. Development and Commercialization Agreement by and...
Exchange Agreements
Clovis Oncology, Inc.
2013
COLLABORATION AND LICENSE AGREEMENT
Collaboration Agreements
Clovis Oncology, Inc.
Biotechnology
DE
2013
CLOVIS ONCOLOGY, INC. 3,333,334 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement
Underwriting Agreements
Clovis Oncology, Inc.
2013
CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT
Indemnification Agreements
Clovis Oncology, Inc.
2013
CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT
Indemnification Agreements
Clovis Oncology, Inc.
2013
CLOVIS ONCOLOGY, INC. [ ] Shares of Common Stock (par value $0.001 per share) Underwriting Agreement
Underwriting Agreements
Clovis Oncology, Inc.
Biotechnology
NY
2012
EMPLOYMENT AGREEMENT
Employment Agreements
Clovis Oncology, Inc.
Biotechnology
CO
2012
CLOVIS ONCOLOGY, INC. INDEMNIFICATION AGREEMENT
Indemnification Agreements
Clovis Oncology, Inc.
2012
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
NY
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
NY
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
NY
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
CO
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
AZ
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
DE
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
CO
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
CO
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
CO
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments
Clovis Oncology, Inc.
Biotechnology
CO
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
DE
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
AZ
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
DE
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
NY
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
CO
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
CO
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
CO
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
DE
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
DE
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
DE
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
DE
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
DE
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
CO
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
NY
2011
Focus on oncology. The oncology market is characterized by a number of disorders with high rates of recurrence and a limited response from current therapies or treatments. Many of...
Clovis Oncology, Inc.
Biotechnology
NY
2011